Exhibit (a)(27)

--------------------------------------------------------------------------------
                     Supplement No. 4 Dated January 25, 2005
     Relating to the Offer to Purchase Dated September 10, 2004, as Amended
--------------------------------------------------------------------------------

                             LOLA BROWN TRUST NO. 1B
                                       and
                           ERNEST HOREJSI TRUST NO. 1B

                  Have Amended Their Offer to Purchase for Cash
               Up to 1,615,000 Outstanding Shares of Common Stock
                                       of
                  NEUBERGER BERMAN REAL ESTATE INCOME FUND INC.
                                       at
                              $19.89 Net Per Share

THE OFFER AND  WITHDRAWAL  RIGHTS  HAVE BEEN  EXTENDED,  AND WILL EXPIRE AT 5:00
P.M., NEW YORK CITY TIME, ON TUESDAY,  MAY 24, 2005, UNLESS THE OFFER IS FURTHER
EXTENDED.

THE OFFER IS NOT  CONDITIONED  UPON THE RECEIPT OF FINANCING OR UPON ANY MINIMUM
NUMBER OF SHARES BEING TENDERED. THE OFFER IS SUBJECT TO CERTAIN CONDITIONS. SEE
"THE OFFER -- SECTION 14."

NEITHER  THE  SECURITIES  AND  EXCHANGE  COMMISSION  NOR  ANY  STATE  SECURITIES
COMMISSION HAS APPROVED OR  DISAPPROVED  OF THIS  TRANSACTION OR PASSED UPON THE
MERITS OR FAIRNESS OF THIS  TRANSACTION  OR PASSED UPON THE ADEQUACY OR ACCURACY
OF THE INFORMATION CONTAINED IN THE OFFER OR THIS SUPPLEMENT. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.

                                    IMPORTANT

     Any shareholder desiring to tender all or any portion of the shareholder's
shares should either:

|X|  Request the shareholder's broker, dealer, commercial bank, trust company or
     other nominee to effect the transaction for the shareholder.  A shareholder
     whose shares are  registered  in the name of a broker,  dealer,  commercial
     bank,  trust  company or other  nominee must  contact such broker,  dealer,
     commercial bank, trust company or other nominee if the shareholder  desires
     to tender such shares; or

|X|  Complete  and sign the letter of  transmittal  (or a facsimile  thereof) in
     accordance with the  instructions  in the letter of  transmittal,  have the
     shareholder's  signature  guaranteed  if required by  Instruction  1 to the
     letter of  transmittal,  mail or deliver the letter of transmittal (or such
     facsimile),  or,  in  the  case  of a  transfer  effected  pursuant  to the
     book-entry  transfer  procedures  set forth in "THE  OFFER --  Section  7,"
     transmit an "agent's message" (as defined in "THE OFFER -- Section 6"), and
     any other  required  documents  to the  depositary  and either  deliver the
     certificates  for such  shares to the  depositary  along with the letter of
     transmittal  (or such  facsimile)  or deliver  the shares  pursuant  to the
     book-entry transfer procedures set forth in "THE OFFER -- Section 7."

If a  shareholder  desires to tender shares and the share  certificates  are not
immediately  available,  or the  procedure  for  book-entry  transfer  cannot be
completed on a timely basis,  or time will not permit all required  documents to
reach the depositary prior to the "expiration  date" (as defined  herein),  then
the tender may be effected by following the procedure  for  guaranteed  delivery
set forth in "THE OFFER -- Section 7."

Questions  and requests for  assistance  may be directed to MacKenzie  Partners,
Inc., the information  agent,  at the address and telephone  number set forth on
the back cover of this  offering  document.  Additional  copies of this offering
document, the letter of transmittal, the notice of guaranteed delivery and other
related materials may be obtained from the information agent.


                    THE INFORMATION AGENT FOR THIS OFFER IS:
                            MACKENZIE PARTNERS, INC.
                               [GRPAHIC OMITTED]




The following  information  amends and  supplements  the Offer to Purchase dated
September 10, 2004 (the "Offer to Purchase"), as amended by the Supplement dated
October 1, 2004 relating to the Offer to Purchase (the "First Supplement"),  the
Supplement  No. 2 dated October 14, 2004  relating to the Offer to Purchase,  as
amended (the "Second  Supplement")  and the  Supplement  No. 3 dated October 26,
2004 relating to the Offer to Purchase, as amended (the "Third Supplement"),  of
the Lola  Brown  Trust No.  1B,  an  irrevocable  grantor  trust  domiciled  and
administered in South Dakota (the "Lola Trust") and the Ernest Horejsi Trust No.
1B, an irrevocable grantor trust domiciled and administered in South Dakota (the
"Ernest Trust" and, together with the Lola Trust, the "Trusts" and also referred
to herein as "we," "our" or "us"),  pursuant to which the Trusts are offering to
purchase up to 1,615,000 of the  outstanding  shares of common stock,  par value
$0.0001 per share (the  "shares")  of Neuberger  Berman Real Estate  Income Fund
Inc., a Maryland  corporation  ("NRL"),  not owned by the Trusts,  at a price of
$19.89 per share,  net to the seller in cash (subject to applicable  withholding
of United States federal,  state and local taxes),  without  interest,  upon the
terms and subject to the  conditions  set forth in this  Supplement No. 4 to the
Offer to Purchase, as amended (the "Fourth  Supplement"),  the Third Supplement,
the Second  Supplement,  the First  Supplement,  the Offer to  Purchase  and the
related  letter  of  transmittal   (which,   together  with  any  amendments  or
supplements thereto, collectively constitute the "Offer").

Except  as  otherwise  set  forth  in this  Fourth  Supplement,  the  terms  and
conditions set forth in the Third Supplement,  the Second Supplement,  the First
Supplement,  the Offer to Purchase and the letter of transmittal  are applicable
in all respects to the Offer.  The information set forth below should be read in
conjunction  with  the  Third  Supplement,  the  Second  Supplement,  the  First
Supplement,  the Offer to Purchase and the letter of  transmittal  and terms not
defined  herein  which are  defined in the Offer to Purchase  have the  meanings
ascribed to them in the Offer to Purchase.


                              QUESTIONS AND ANSWERS

How have you amended the offer?

     We are amending our offer to extend the expiration date,  reduce the number
     of shares being sought, and to provide you with the additional  information
     regarding the offer set forth below in this Fourth Supplement.  We have not
     changed the offer price,  the  procedures  for  tendering  and  withdrawing
     shares or any of the other  terms of our offer  other  than the  expiration
     date.

What is the new expiration date for the offer?

     We are extending the  expiration  date for the offer to 5:00 P.M., New York
     City Time on Tuesday, May 24, 2005, unless further extended.

Why did you extend the expiration date for the offer?

     In order to halt the offer, last September NRL's Board of Directors adopted
     a  shareholder  rights plan or poison pill,  which,  as required by federal
     law,  expired on January 21,  2005.  Our offer was  scheduled  to expire on
     January  25,  2005.  However,  NRL's Board of  Directors  has now adopted a
     second poison pill, virtually identical to the first one. The second poison
     pill will expire on May 18, 2005.  The validity of the second  poison pill,
     and whether  NRL's Board of  Directors  can  continue to adopt poison pills
     indefinitely, are two of the issues in our litigation with NRL.

     Because we cannot  close the offer while  NRL's  poison  pills  continue to
     exist,  we do not expect to close the offer unless we are successful in our
     litigation against NRL's poison pills as well as certain of the other steps
     NRL has taken to halt the offer.  On October 22, 2004, the federal court in
     Maryland  issued  a  Memorandum  Opinion  and  Declaratory  Judgment  Order
     upholding the validity of NRL's first poison pill, which we refer to as the
     "poison  pill  order." We have filed an appeal of the poison  pill order to
     the United States Court of Appeals for the Fourth Circuit. We have extended
     the  expiration  date for our offer to  preserve  our offer while we pursue
     this appeal and seek a final  judgment  in our favor with  respect to NRL's
     second poison pill and other matters involved in the litigation.

Can you extend the offer again?

     We may, but are not required  to,  extend the offer again  depending on the
     results of our  attempt to appeal the poison pill order and to seek a final
     judgment in our favor with respect to NRL's  poison pill and other  matters
     involved  in our  litigation  with NRL. We may also extend the offer in our
     discretion  for other  reasons,  and we will  extend the offer again if the
     rules of the Securities and Exchange  Commission require us to do so. If we
     extend our offer again, we will make a public announcement of the extension
     by no later than 9:00 a.m.,  New York City time,  on the next  business day
     after the day on which our offer was scheduled to expire.  See "THE OFFER -
     Section 5."

Why are you tendering for fewer shares?

     We are seeking ownership of a majority of NRL's outstanding shares. Because
     of NRL's issuer tender offer last fall, there are fewer outstanding  shares
     now, and, accordingly,  we have reduced the number of shares we are seeking
     to  acquire.  The number of shares we are  offering to  purchase,  plus the
     number of shares we already own, will be a majority of the shares currently
     outstanding.



What happens if stockholders tender more than the reduced number of shares you
are willing to buy?

     If  stockholders  tender more than the reduced number of shares that we are
     willing to buy, we will  purchase  shares on a pro-rata  basis.  This means
     that we will  purchase  the  same  ratio  of  shares  from  each  tendering
     stockholder.  For  example,  if two shares are  tendered for every share we
     purchase in the offer,  we will  purchase  50% of the number of shares that
     you tender.  We will make  adjustments  to avoid  purchases  of  fractional
     shares.

What actions have you and NRL taken in the litigation between you and NRL?

     On  September  23,  2004,  NRL  announced  that its  board  authorized  the
     commencement  of a lawsuit  against us in the United States  District Court
     for the District of Maryland,  seeking to enjoin us from  consummating  our
     offer on the basis that we allegedly  made material  false  statements  and
     omissions in our Offer to Purchase.  The commencement of litigation against
     us was one of a series of steps designed to defeat our offer taken by NRL's
     board on September 23, 2004, including:

     |X|  recommending that NRL's  shareholders  reject our offer and not tender
          their shares to us for purchase;

     |X|  issuing 139,535 shares to Neuberger Berman, LLC, a sub-adviser to NRL,
          for $21.50 per share and an aggregate of $3,000,002.50,  pursuant to a
          common stock purchase agreement;

     |X|  adopting  resolutions  effective  immediately  after the  issuance  of
          shares to Neuberger Berman,  LLC pursuant to which it is intended that
          NRL would be subject to the Maryland Control Share  Acquisition Act as
          well as the Maryland Business Combination Act;

     |X|  authorizing  NRL to commence an issuer tender offer for 943,704 shares
          at a price of $20.00 per share,  even though the NRL board recommended
          that  shareholders not tender their shares in the issuer tender offer;
          and

     |X|  adopting a poison pill.

     We responded to these defensive measures by filing  counter-claims  against
     NRL with the court on October 6, 2004,  seeking,  among  other  things,  to
     invalidate  the poison pill and NRL's attempt to apply  Maryland's  control
     share  statute to us and our offer.  We also seek in our  counterclaims  to
     prevent the  consummation of NRL's self tender on the basis that NRL's self
     tender materials contained material misstatements and omissions. On October
     22, 2004, the court issued the poison pill order  upholding the validity of
     NRL's  poison  pill.  The  court did not rule on the  applicability  of the
     Maryland  Control Share  Acquisition Act, but commented that "it would seem
     unfair to allow NRL to invoke [the  control  share act]  against the Trusts
     under these circumstances." In addition,  the court did not address whether
     the Trusts'  ownership  of more than 3% of the Fund's  shares  violated the
     Investment Company Act of 1940. A copy of the poison pill order is attached
     as Exhibits  a(25) and a(26) to Amendment  No. 4 to the Schedule TO we have
     filed with the SEC.

     We have filed an appeal of the poison pill order to the United States Court
     of Appeals  for the Fourth  Circuit in order to obtain a final  judgment in
     our favor  invalidating  NRL's poison  pill.  We also intend to continue to
     seek to have the court enter a final  judgment in our favor with respect to
     the other  matters  involved  in our  litigation  with NRL,  including  the
     application  of Maryland's  control share act to us and our offer and NRL's
     claim that our ownership of more than 3% of NRL's outstanding  voting stock
     violates  the  Investment  Company  Act of 1940.  In  light  of this  court
     activity and NLR's adoption of the second poison pill, we elected to extend
     the offer to 5:00 p.m. New York City time on Tuesday, May 24, 2005.

Will you accept shares tendered in the offer for payment if you are not
successful in obtaining a court ruling against NRL?

     Each of the defensive  measures taken by NRL's board on September 23, 2004,
     as well as the  adoption  by the NRL  board of the  second  poison  pill on
     January 18, 2005,  will prevent one or more of the  conditions to our offer
     from being met.  See "THE OFFER - Section  14." We do not intend to rely on
     the  announcement,  commencement or consummation of NRL's self tender offer
     as grounds for  avoiding or delaying our  obligation  to accept for payment
     and pay for  tendered  shares.  However,  we do not  expect to  accept  for
     purchase  the  shares  tendered  in our offer if we are not  successful  in
     obtaining a final judgment against NRL invalidating the second poison pill,
     finding that the Maryland  control  share  statute does not apply to us and
     our  offer,  and  finding  that  our  ownership  of more  than 3% of  NRL's
     outstanding  voting  stock does not violate the  Investment  Company Act of
     1940.

What were the results of NRL's self tender offer?

     According  to  Amendment  No. 6 to NRL's  Schedule TO filed by NRL with the
     Securities and Exchange  Commission on November 4, 2004,  NRL's self tender
     offer for up to 943,704  shares,  including  the  associated  common  stock
     purchase rights,  at $20.00 net per share,  expired at 12:00 Midnight,  New
     York City time, on Friday,  October 29, 2004, and, based on the final count
     by NRL's Depositary, The Bank of New York, 561,401 shares were tendered for
     purchase for cash in NRL's self tender  offer,  representing  approximately
     11.9% of the total outstanding shares.

     We did not tender any shares for purchase in NRL's self tender offer.  As a
     result of the purchase by NRL of 561,401  shares in its self tender  offer,
     the percentage of outstanding  shares held by us has increased to 11.65% in
     the aggregate based on 4,017,582  outstanding shares  (4,157,116.626 shares
     outstanding  as of January 18, 2005,  according  the NRL's filings with the
     SEC,  other than the 139,535  issued  shares to  Neuberger  Berman,  LLC on
     September  22,  2004,  which we believe  were not validly  issued).  If the
     139,535 shares issued by NRL to Neuberger Berman, LLC on September 22, 2004
     were validly issued,  then our ownership would be 11.26% of the outstanding
     shares.



If I already tendered my shares in the offer, do I have to do anything now?

     No.  Shareholders who validly tendered their shares previously and have not
     withdrawn  them do not have to take any  further  action.  If the  Offer is
     completed,  these  shares  will be accepted  for payment and the  tendering
     shareholders  will  receive  the offer  price of $19.89  per share in cash,
     without interest, less any required withholding taxes.

Can I withdraw my previously tendered shares?

     You may withdraw all or a portion of your tendered shares at any time prior
     to the time the shares are accepted for payment, after which they cannot be
     withdrawn. See "THE OFFER -- Section 8."

How do I withdraw previously tendered shares?

     To withdraw  shares,  you must deliver a written notice of withdrawal  with
     the required  information to the depositary  while you still have the right
     to  withdraw  the  shares.  If you have  tendered  your  shares  by  giving
     instructions to a bank, broker, dealer, trust company or other nominee, you
     must instruct them to arrange for the  withdrawal of your shares.  See "THE
     OFFER -- Section 8."

How many shares have been tendered in response to your offer?

     As of the close of business on January 21,  2005,  261,025  shares had been
     tendered for sale to us in response to our offer.

Who can I contact if I have additional questions about the offer?

     If you have questions or you need assistance,  you should contact MacKenzie
     Partners,  Inc.,  the  information  agent for the offer,  at (212) 929-5500
     (collect) or (800) 322-2885 (toll-free).

                                  MISCELLANEOUS

The Offer is not being made to, nor will  tenders be accepted  from or on behalf
of,  holders of shares in any  jurisdiction  in which the making of the Offer or
the acceptance thereof would not comply with the laws of that  jurisdiction.  We
are not aware of any jurisdiction in which the making of the Offer or the tender
of shares in connection  therewith  would not be in compliance  with the laws of
such jurisdiction. If we become aware of any state law prohibiting the making of
the Offer or the acceptance of shares  pursuant  thereto in such state,  we will
make a good faith  effort to comply with any such state  statute or seek to have
such state statute declared inapplicable to the Offer. If, after such good faith
effort, we cannot comply with any such state statute, the Offer will not be made
to (nor will tenders be accepted  from or on behalf of) the holders of shares in
such jurisdiction.  In any jurisdiction where the securities,  blue sky or other
laws  require  the Offer to be made by a licensed  broker or  dealer,  the Offer
shall be deemed to be made on  behalf  of the  Trusts by one or more  registered
brokers or dealers which are licensed under the laws of such jurisdiction.

No  person  has  been  authorized  to  give  any  information  or  to  make  any
representation  on our behalf not  contained in the Offer and, if given or made,
that  information  or  representation  must  not be  relied  on as  having  been
authorized.

We filed with the SEC a Schedule TO dated September 10, 2004, an Amendment No. 1
to Schedule TO dated  October 1, 2004,  an Amendment  No. 2 to Schedule TO dated
October 7, 2004,  an Amendment  No. 3 to Schedule TO dated  October 14, 2004, an
Amendment  No. 4 to Schedule TO dated October 26, 2004 and an Amendment No. 5 to
Schedule TO dated November 5, 2004 under Exchange Act Rule 14d-3,  together with
exhibits,  furnishing additional  information with respect to the Offer, and may
file additional  amendments  thereto.  That schedule and any amendments thereto,
including exhibits,  may be examined and copies may be obtained from the offices
of the SEC in the same  manner as  discussed  in "THE OFFER -- Section  12" with
respect to information concerning NRL.

                                                          LOLA BROWN TRUST NO.1B
                                                      ERNEST HOREJSI TRUST NO.1B

January 25, 2005






     Facsimile copies of the letter of transmittal, properly completed and duly
executed, will be accepted. The letter of transmittal, certificates for shares
and any other required documents should be sent or delivered by each shareholder
of NRL or his or her broker, dealer, commercial bank, trust company or other
nominee to the depositary at one of its addresses set forth below:

                        The Depositary for the Offer is:

                             The Colbent Corporation

                                                                                             

                 By Mail:                               By Overnight Courier:                              By Hand:
          The Colbent Corporation                      The Colbent Corporation                     The Colbent Corporation
          Attn: Corporate Actions                      Attn: Corporate Actions                     Attn: Corporate Actions
                POB 859208                               161 Bay State Drive                         161 Bay State Drive
          Braintree MA 02185-9208                        Braintree MA  02184                         Braintree MA  02184



                                  By Facsimile:
                                 (781-380-3388)

                         Confirm Facsimile Transmission:
                             (781-843-1833 Ext. 200)

     Questions and requests for  assistance  may be directed to the  information
agent at its address and telephone  numbers listed below.  Additional  copies of
this  Supplement,  the Offer to Purchase,  the letter of  transmittal  and other
tender offer materials may be obtained from the information  agent,  and will be
furnished  promptly at our expense.  You may also  contact your broker,  dealer,
commercial  bank,  trust company or other nominee for assistance  concerning the
Offer.



                     The Information Agent for the Offer is:
                            MACKENZIE PARTNERS, INC.
                               [GRAPHIC OMITTED]
                               105 Madison Avenue
                            New York, New York 10016
                          (212) 929-5500 (Call Collect)
                                       or
                           (800) 322-2885 (Toll Free)

                       E-MAIL: proxy@mackenziepartners.com